

### Certificate of Analysis

### DCAMKL3, active (Recombinant enzyme expressed in Sf21 insect cells) Item # 14-943, 14-943-K, 14-943M Parent Lot # D14CP007N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** *N*-terminal 6Histagged, recombinant, human DCAMKL3 amino acids 345-end, expressed by baculovirus in Sf21 insect cells. Purified using immobilized metal affinity chromatography followed by gel filtration. Purity 97% by SDS-PAGE and Coomassie blue staining. MW = 38kDa.

Specific Activity (Parent lot# D14CP007N): 2527U/mg, where one unit of DCAMKL3, active activity is defined as 1nmol phosphate incorporated into 250μM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100μM.

**Formulation: 0.365mg/ml** of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


# FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

#### **Quality Control Testing**

<u>Kinase Assay</u>: 0.5–11.4ng of this lot of enzyme phosphorylated 250μM (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as DCAMKL3 with the translated sequence listed on page three



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of DCAMKL3, active

Eurofins Pharma Discovery Services UK Limited Gemini Crescent Dundee Technology Park DUNDEE DD2 1SW United Kingdom T | +44 (0)1382 561600 F | +44 (0)1382 561601 www.eurofins.com/pharmadiscovery



## **Certificate of Analysis**

#### **Kinase Assay Protocol**

#### Stock Solutions:

- 5 x Reaction Buffer: 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. (KKLNRTLSFAEPG): Use at a final assay concentration of 250μM. Prepare a 2.5mM stock and add 2.5μl of stock per assay point.
- 3. DCAMKL3, active: Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.5—11.4ng per assay point.
- **4.** [γ-<sup>33</sup>P]ATP: 2.5 x MgAc/[γ<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ<sup>33</sup>P]ATP (specific activity approximately 500 800cpm/pmol as required).

#### Assay Procedure (96 well plate format):

- 1. Add 5µl of 5 x reaction buffer per assay to wells.
- 2. Add 2.5µl of (KKLNRTLSFAEPG).
- 3. Add 2.5µl (0.5-11.4ng) DCAMKL3, active.
- 4. Add 5µl of dH<sub>2</sub>O.
- 5. Add 10 $\mu$ l of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
- 6. Incubate for 10 minutes at 30°C.
- 7. Stop the reaction by adding 5µl of 3% phosphoric acid.
- 8. Transfer a 10µl aliquot onto the appropriate area of a P30 Filtermat.
- 9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
- 10. Wash the filtermat once for 2 minutes with methanol.
- 11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
- 12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µI of 30% phosphoric acid.

### Certificate of Analysis

#### **DCAMKL3 Sequence Information**

<u>Protein</u> human DCAMKL3

Tags N-terminal 6His

Native sequence M31 of the recombinant protein is equivalent to M345 of human DCAMKL3

Accession number GenBank NM\_033403

#### Recombinant DCAMKL3 amino acid sequence:

```
1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MGIIAANVEK HYETGRVIGD GNFAVVKECR
61 HRETRQAYAM KIIDKSRLKG KEDMVDSEIL IIQSLSHPNI VKLHEVYETD MEIYLILEYV
121 QGGDLFDAII ESVKFPEPDA ALMIMDLCKA LVHMHDKSIV HRDLKPENLL VQRNEDKSTT
181 LKLADFGLAK HVVRPIFTVC GTPTYVAPEI LSEKGYGLEV DMWAAGVILY ILLCGFPPFR
241 SPERDQDELF NIIQLGHFEF LPPYWDNISD AAKDLVSRLL VVDPKKRYTA HQVLQHPWIE
301 TAGKTNTVKR QKQVSPSSEG HFRSQHKRVV EQVS
```

#### Recombinant DCAMKL3 nucleotide sequence:

```
1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
 61 tattttcagg gcgccatgga tccggaattc atgggcatca ttgccgccaa tgtggaaaag
121 cattatgaga ctggccgggt cattggggat gggaactttg ctgtcgtgaa ggagtgcaga
181 caccgcgaga ccaggcaggc ctatgcgatg aagatcattg acaagtccag actcaagggc
241 aaggaggaca tggtggacag tgagatcttg atcatccaga gcctctctca ccccaacatc
301 gtgaaattgc atgaagtcta cgaaacagac atggaaatct acctgatcct ggagtacgtg
361 cagggaggag acctttttga cgccatcata gaaagtgtga agttcccgga gcccgatgct
421 gccctcatga tcatggacct atgcaaagcc ctcgtccaca tgcacgacaa gagcattgtc
481 caccgggacc tcaagccgga aaaccttttg gttcagcgaa atgaggacaa atctactacc
541 ttgaaattgg ctgattttgg acttgcaaag catgtggtga gacctatatt tactgtgtgt
601 gggaccccaa cttacgtagc tcccgaaatt ctttctgaga aaggttatgg actggaggtg
661 gacatgtggg ctgctggcgt gatcctctat atcctgctgt gtggctttcc cccattccgc
721 agccctgaga gggaccagga cgagctcttt aacatcatcc agctgggcca ctttgagttc
781 ctccccctt actgggacaa tatctctgat gctgctaaag atctggtgag ccggttgctg
841 gtggtagacc ccaaaaagcg ctacacagct catcaggttc ttcagcaccc ctggatcgaa
901 acagctggca agaccaatac agtgaaacga cagaagcagg tgtcccccag cagcgagggt
961 cacttccgga gccagcacaa gagggttgtg gagcaggtat catag
```

#### Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services